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1. ABSTRACT: 
Endothelial dysfunction is one of the primary factors in the onset and progression of 
atherothrombosis resulting in acute myocardial infarction (AMI). However, the pathological 
and cellular mechanisms of endothelial dysfunction in AMI have not been systematically 
studied. Protein expression profiling in combination with a protein network analysis was 
employed using a mass spectrometry-based label-free quantification approach. This identified 
and quantified 2,246 proteins, of which 335 were differentially regulated in coronary arterial 
endothelial cells from patients with AMI compared to controls. The differentially regulated 
protein profiles reveal the alteration of a) metabolism of RNA, b) platelet activation, signalling 
and aggregation, c) neutrophil degranulation, d) metabolism of amino acids and derivatives, e) 
cellular responses to stress, and f) response to elevated platelet cytosolic Ca2+ pathways. 
Increased production of oxidants and decreased production of antioxidant biomarkers as well 
as down regulation of proteins with antioxidant properties suggests a role for oxidative stress 
in mediating endothelial dysfunction during AMI. In conclusion, this is the first quantitative 
proteomics study to evaluate the cellular mechanisms of endothelial dysfunction in patients 
with AMI. A better understanding of the endothelial proteome and pathophysiology of AMI 
may lead to the identification of new drug targets. 
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2. Introduction: 
The vascular endothelium plays a key role in the maintenance of homeostasis and it also acts 
as a multi-functional organ for vascular tone regulation. Endothelial dysfunction is more 
frequently observed in patients with cardiovascular risk factors and contributes to the 
development of atherogenesis, hypertension, peripheral vascular disease, chronic kidney 
failure, diabetes, viral infections, coronary artery disease, and myocardial ischemia1–5. It is 
characterized by several features including the association of increased production of reactive 
oxygen species (ROS), growth factors, adhesive molecules; impaired redox status and 
fibrinolytic ability; a discrepancy in the functions of endothelium-mediated vasodilation, 
prothrombic and proinflammatory responses6–8. Alterations in endothelial function contribute 
to the development, progression and clinical manifestations of atherosclerosis9. 
Acute myocardial infarction (AMI) is one of the leading causes of morbidity and mortality 
throughout the world and the prevalence of this disease is increasing rapidly in developing 
countries. Worldwide it is estimated that there were 15.9 million cases of AMI in 201510. AMI 
is the most common manifestation of the acute coronary syndrome, occurring as a consequence 
of coronary thrombosis and a reduction in myocardial perfusion. The rupture of an 
atherosclerotic plaque or erosion of the coronary endothelial monolayer exposes blood to 
thrombogenic lipids, which leads to the activation of clotting factors and platelets. 
Atherosclerotic plaque with a thin fibrous cap and lipid-rich core are more prone to rupture. 
Previous studies have shown that circulating microparticles are increased in patients with AMI 
and endothelial dysfunction occurs in young patients with AMI irrespective of whether they 
have conventional cardiovascular risk factors11,12. 
Emerging data specifies that pathological blood vessel responses and endothelial dysfunction 
are associated with metabolic alterations in endothelial cells (ECs)13.  However, the underlying 
mechanisms associated with endothelial dysfunction may be multidimensional and have not 
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been fully defined. Therefore, insights into the cellular mechanisms of endothelial dysfunction 
may aid our understanding of the acute coronary syndrome and lead to the development of new 
therapeutic tools. In this study, we aimed to identify the differentially regulated proteins 
associated with the endothelial dysfunction in patients with AMI. For this purpose, we isolated 
primary ECs from the thrombotic material aspirated from the coronary arteries of patients 
undergoing treatment for acute ST-segment elevation myocardial infarction. We applied a mass 
spectrometry-based label-free quantification approach to evaluate the molecular mechanisms, 
network and signalling pathways associated with endothelial dysfunction in AMI.  
3. Methods: 
Data available on request from the authors. Total protein was extracted from control and 
pathological ECs and subjected to reduction followed by alkylation. In-solution trypsin 
digested peptides were separated by nano LC-HRMS analysis. The resulting raw files were 
analysed by using various software for the protein identification, quantification. Statistically 
significantly differentially regulated proteins were used for gene ontology, network and 
pathway analysis. See supplemental materials and methods for the detailed procedures.  
4. Results:  
4.1 Identification and differential proteomic analysis of dysfunctional ECs 
The aim of this study was to identify the differentially regulated proteins associated with 
endothelial dysfunction in AMI. For this purpose, primary ECs were isolated from the 
atherothrombotic material aspirated from the occluded coronary artery in patients with AMI. A 
mass spectrometry-based label-free quantitation approach enables the evaluation of the 
complex network and signalling pathways associated with the endothelial dysfunction. The 
confluent HCAEC-AMI and normal HCAECs were collected to extract the protein content. 
Altered protein expression profiling in combination with gene ontology, network and pathway 
analysis was employed by using the mass spectrometry-based label-free quantification 
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approach to explore the molecular mechanisms. Multi scatter plot analysis of peptide intensities 
resulted in Pearson coefficients higher than 0.98, attesting the high grade of reproducibility of 
technical and biological replicates. 2246 protein and 17653 unique peptides were quantified, 
consulting the Uniprot_Homosapiens database; the settings of searches were 10 ppm tolerance 
on peptides, 0.8Da on fragments and less than 1% false discovery rate. The data analysis was 
performed as specified in our publication14. To discriminate the differentially expressed 
proteins a two-sided t test was applied to two category groups: HCAEC-AMI (disease) and 
HCAEC (control). The log2 of ratios of disease versus control (fold change) were plotted 
against the -log10 of p-value, resulting in the Volcano plot of Figure 1. All proteins with a fold 
change higher than 1.5 and p-value less than 0.05 were considered significant because these 
proteins differed from most quantified proteins (with fold change about 1) whose expression 
in patient samples did not change related to controls.  335 proteins were differentially regulated, 
of which 40 and 123 proteins were up- and down-regulated respectively, with a fold change 
higher than 1.5 in the HCAEC-AMI cells compared to control cells (Table 1a and 1b). 
4.2 Endothelial dysfunction and upregulation  
The majority of upregulated proteins in HCAEC-AMI cells originated from the proteasome 
complex, nucleosome, nuclear nucleosome, or large ribosomal subunit and cytosolic ribosome 
(Table S1). The actin-binding protein TMSB10 was upregulated in dysfunctional ECs with a 
log2 fold change of 2.68. This protein is involved in actin filament organization and plays an 
important role in the cytoskeleton. Similarly, we identified vonWilibrand Factor (vWF), an 
important adhesion protein, was upregulated with a 2.06 log2 fold change. vWF is a key protein 
in vascular hemostasis, blood coagulation, platelet degranulation and activation, and in 
extracellular matrix organization. Studies have shown that vWF promotes the formation of a 
molecular bridge between platelet-surface receptor complex GPIb-IX-V and sub-endothelial 
collagen matrix, which further increases the binding of platelets to the site of vascular injury. 
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The plasminogen activator (PLAT) protein involved in tissue remodelling and degradation was 
also upregulated in dysfunctional ECs. Along with these proteins, based on our results, a 
platelet-expressed protein HSD17B12 might play a role in the pathogenesis of coronary artery 
disease. This protein has 3-ketoacyl-CoA reductase activity, suggesting a role in lipid 
metabolism and fatty acid biosynthesis. Other differentially regulated proteins and their  
associated biological processes are reported in Figure 2a. 
4.3 Endothelial dysfunction and down-regulation 
Cytosolic small and large ribosomal subunits and proteasome complex were the major sources 
of down-regulated proteins (Table S2). These proteins are involved in ribosome biosynthesis, 
small and large subunit assembly, the regulation of cardiac muscle contraction by the release 
of sequestered calcium ions, regulation of oxidative stress-induced cell death, cellular 
responses to reactive oxygen species, and cellular aldehyde metabolic processes (Figure 2b, 
Table S3). UBE2I, SYNE1, and MGST1 showed extensive downregulation among all the 
identified proteins. The MAPEG family (Membrane-Associated Proteins in Eicosanoid and 
Glutathione metabolism) protein MGST1, is involved in the protection of the endoplasmic 
reticulum and outer mitochondrial membrane from oxidative stress. Therefore, the 
downregulation of this protein in dysfunctional ECs might indicate increased oxidative stress 
in endothelial cells during AMI. 
4.4 Network and pathway analysis: To better understand the nature of differentially regulated 
proteins, they were further classified in terms of reactome pathways. Data from this analysis 
showed the association of a) metabolism of RNA, b) platelet activation, signaling and 
aggregation, c) neutrophil degranulation, d) metabolism of amino acids and derivatives, e) 
platelet degranulation, f) cellular responses to stress, and g) response to elevated platelet 
cytosolic Ca2+ pathways in endothelial dysfunction of AMI (Figure 3). 
4.5 Validation of protein by western blot:  
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To validate the expression of vWF, we used western blot analysis. The peak intensity area of 
each protein band was calculated using ImageJ software and the data illustrated as histograms 
after analyzing against the ß- actin as housekeeping protein. As shown in Figure 4, the relative 
abundance of vWF protein in the dysfunctional ECs was analogous to the results from label-
free quantification study.  
5. Discussion: 
A deep understanding of the molecular mechanisms of disease is crucial in the discovery of 
novel therapeutic strategies for the treatment of endothelial dysfunction and its associated 
vascular diseases. Mass spectrometry-based proteomics is one of the advanced tools to identify 
new biomarkers and therapeutic targets. In the present study, for the first time, we describe the 
change in proteome profile of coronary arty endothelial cells in patients with AMI. 
The endothelium which exists between the circulatory system and surrounding tissues plays an 
important role in protecting the vascular from injury. Based on local sheer stress and tissue 
requirements, ECs can create a prothrombotic or antithrombotic environment. Usually, healthy 
ECs express anticoagulant and antiplatelet proteins that prevent fibrin formation and platelet 
aggregation. Whereas dysfunctional ECs stimulate platelet aggregation and adhesion, and 
fibrin formation. ECs are also able to produce pro-fibrinolytic proteins, such as tissue 
plasminogen activate to enhance the fibrinolysis and promote degradation of local thrombus. 
In this study TMSB10 and vWF proteins were highly upregulated. TMSB10 has a role in the 
organization of the cytoskeleton, while the increased expression of vWF would be expected to 
enhance thrombus formation in the coronary artery. vWF also binds to collagen which plays a 
key role in the maintenance of the integrity and elasticity of the vasculature as well and when 
the vessel is injured and the prothrombotic collagen matrix exposed this interaction could 
precipitate AMI15. Interestingly, mass spectrometry based iTRAQ analysis with vascular 
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smooth muscle cells (VSMCs) isolated from the aortic wall of MI patients also revealed the 
overexpression of VWF protein16. 
Over expression of vWF, RAP1A, and RAP1B proteins would also promote platelet 
aggregation via the integrin alpha IIb beta3 signaling and MAP2K and MAPK activation 
pathways. MAPKs are implicated in multiple important cellular processes such as apoptosis, 
cellular proliferation, motility, differentiation, stress response, and survival. In this study, 
MAPK3 was down regulated, suggesting that endothelial cells from patients with AMI may 
have lower proliferation capability. Recent studies have shown that the interferon-induced 
GTP-binding protein MX1 is involved in AMI17,18. In this study, MX1 was upregulated with a 
2.4-fold change, supporting a role for this protein in endothelial dysfunction. Rap1, which 
controls EC function, is one of the critical mediators of FGF-induced ERK activation in 
angiogenesis19. In this study, RAP1a and RAP1b were upregulated in patient-derived ECs 
perhaps to facilitate angiogenesis and promote myocardial salvage following AMI. RAP1a and 
1b may also play a role in the protection of vascular ECs, based on the results of knockdown 
studies20. 
The identified differentially regulated proteins in our patient-derived endothelial cells, such as 
VWF21, CRYAB22, MX123, CNN224,25, PSME226, CIAPIN127, TAGLN28, and EDIL329 have 
previously been reported to be implicated in AMI, vascular injury, morphogenesis, and 
angiogenesis in experimental models of disease. Furthermore, previous studies have shown the 
increased synthesis of type VIII collagen in the development of atherosclerosis in both humans 
and animal models30,31. The over expressed HSD17B12 protein is a reductase involved in 
collagen binding activity and long fatty acid chain metabolism. However, in the case of 
dysfunctional ECs of disease, HSD17B12 was down regulated, suggesting a different role in 
these diseases. MMRN1, belonging to EMILIN family32, is usually found in platelets, and has 
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an adhesive ligand property in synergy with vWF in platelet adhesion to collagen at the sites 
of vascular injury33,34. 
EC apoptosis has a fundamental role in the angiogenesis process and pathological vascular 
remodelling and regression35–37. In this study proteins related to apoptosis pathway were 
differentially regulated. In particular, CYCS, DNM1L, HMGB1, LMNB1, PSMA4, PSMA7, 
PSMB5, PSMC5, PSMD13, PSME1, YWHAB, YWHAE showed decreased expression and 
PSMA2, PSMB3 (1.08-fold change) and PSME2 showed increased expression, attesting their 
prominent role during endothelial reorganization in AMI. 
Metabolic alterations and oxidative stress are important inducers of endothelial dysfunction in  
cardiovascular diseases and diabetes mellitus38–40. Normal ECs constantly produce endothelial 
nitric oxide synthase (eNOS). Impairment of the eNOS–NO system causes oxidative stress and 
endothelial dysfunction that accelerates atherogenesis. In this investigation, a reduced 
expression of eNOS activation pathway, evidenced by the downregulation of CALM1, 
CALM2, and CALM3 proteins, and the activation of NF-kappaB were observed. PARK7, 
PAWR, PSAP, TXN and UBQLN1 proteins, involved in the regulation of oxidative stress-
induced cell death, and MGST1 protein, involved in the cell protection against oxidative stress, 
were also down regulated. Moreover, the overexpression of superoxide dismutase (SOD1) was 
involved in hypoxia response and superoxide radical degradation pathways in VSMCs of 
patients with MI41. This confirms the involvement of oxidative stress in endothelial 
dysfunction. The inhibition of vascular oxidative stress and enhancement of endothelial NO 
production could be a potential therapeutic strategy along with the treatments of established 
risk factors. 
Ribosome (including RNA and proteins) is an essential component in the machinery of protein 
synthesis and ribosomal proteins (RPs) plays a critical role in the cell proliferation, 
differentiation, apoptosis, DNA repair, and other cellular processes42. Studies have shown that 
9 
 
the dysfunction of ribosomal biosynthesis may result in abnormal cell proliferation in 
metabolic disorders and cancer43,44. Moreover, various RPs have been reported to be associated 
with the progression of cardiovascular diseases45,46. However, we observed the downregulation 
of several RPs in dysfunctional ECs which are corresponding to the ribosome biogenesis, small 
and large subunit assembly processes. 
6. Perspectives: 
In this study, the main involved pathways and related proteins have been extensively described 
and they will be further investigated in clinical prospective. This protein atlas in underlying 
mechanism of endothelial dysfunction can provide new perspectives in drug discovery for the 
treatment of cardiovascular diseases.  
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10. Novelty and significance of the work:  
What is new?  
In this study we define the proteomic signature of endothelial cells derived from patients with 
acute myocardial infarction and identify plausible pathophysiological mechanisms of 
endothelial dysfunction.  
What is relevant?  
Quantitative proteomic profiling in endothelial dysfunction revealed the biomarker signature 
of thrombosis, metabolism and oxidative stress. The overexpression of VWF strongly 
associated with thrombus formation, platelet aggregation and angiogenesis that might play a 
key role endothelial dysfunction of AMI. Increased production of oxidants and decreased 
production of antioxidant biomarkers, as well as down regulation of proteins which had an 
antioxidant property, strongly suggest a role for oxidative stress in the endothelial dysfunction 
of AMI.  
Summary 
Our mass spectrometry-based label-free quantitative proteomics approach revealed several 
cardiovascular related biomarkers in AMI. Thrombus formation, collagen deposition, vascular 
remodeling, platelet aggregation, metabolic alterations, oxidative stress related events have a 
potential unfavorable impact on the endothelial dysfunction. 
11. Figure and Table Legends: 
Figure 1: Distribution of differentially regulated proteins in HCAEC-AMI cells. Volcano Plot 
obtained by two-sided t test of the groups: HCAEC-AMI (disease) versus HCAEC (control). 
Dots on the left indicates the down-regulated proteins, dots on the right represents the 
upregulated ones. 
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Figure 2: Biological processes associated with up (a) and down (b) regulated proteins found 
in dysfunctional HCAEC-AMI cells. The significance of the clustering is shown by the size of 
nodes. 
Figure 3: Main pathways and involved genes found in dysfunctional HACEC-AMI cells. 
ClueGo analyses enriched and clustered Reactome pathway terms. The significance of the 
clustering is shown by the size of nodes. 
Figure 4: : Protein expression levels of selected proteins. Bar graph was plotted with mean ± 
SEM, the x-axis represents the HCAEC-AMI and HCAEC groups and the y-axis represents the 
relative expression of a respective protein to control. Differences were considered significant 
when p < 0.05 (*), 0.001 < p < 0.01 (**), p < 0.001 (***). β-actin was used as a housekeeping 
protein. 
Table 1a: List of upregulated proteins associated with endothelial dysfunction in AMI. 
Table 1b: List of down-regulated proteins associated with endothelial dysfunctionality in AMI. 
12. Tables:  
Table 1a: 
Protein ID Protein names 
Gene 
names 
Log2 
(HCAE
C-AMI 
vs 
HCAE
C) 
-LOG(P-
value) 
P63313 Thymosin beta-10 TMSB10 2.68 4.97 
P04275 
von Willebrand factor;von Willebrand 
antigen 2 
VWF 2.06 1.41 
18 
 
B4DWS6 
Very-long-chain 3-oxoacyl-CoA 
reductase 
HSD17B
12 
1.47 5.70 
E9PR44 Alpha-crystallin B chain CRYAB 1.43 3.29 
B4DRD3 
Tissue-type plasminogen 
activator;Tissue-type plasminogen 
activator chain A;Tissue-type 
plasminogen activator chain B 
PLAT 1.37 13.16 
A0A140VJL6 
Isoamyl acetate-hydrolyzing esterase 
1 homolog 
IAH1 1.33 5.87 
P20591 
Interferon-induced GTP-binding 
protein Mx1;Interferon-induced GTP-
binding protein Mx1, N-terminally 
processed 
MX1 1.25 3.67 
O95433 
Activator of 90 kDa heat shock 
protein ATPase homolog 1 
AHSA1 1.20 3.35 
B4DDF4 Calponin;Calponin-2 CNN2 1.06 4.70 
Q86SZ7 
Proteasome activator complex subunit 
2 
PSME2 1.03 2.36 
B4E2S7 
Lysosome-associated membrane 
glycoprotein 2 
LAMP2 1.03 3.60 
Q6FI81 Anamorsin CIAPIN1 0.99 6.26 
A0A0S2Z4G7 Nucleophosmin NPM1 0.93 3.75 
A0A024R6I3 
Transmembrane emp24 domain-
containing protein 10 
TMED10 0.91 5.50 
19 
 
Q6IBN4 
Enoyl-CoA delta isomerase 2, 
mitochondrial 
PECI 0.86 5.85 
O94874 E3 UFM1-protein ligase 1 UFL1 0.85 3.59 
O15511 
Actin-related protein 2/3 complex 
subunit 5 
ARPC5 0.84 2.69 
A0A024R3C4 KDEL motif-containing protein 2 KDELC2 0.84 3.28 
Q5RLJ0 UPF0568 protein C14orf166 
C14orf16
6 
0.83 8.21 
Q9UPN1 
Serine/threonine-protein 
phosphatase;Serine/threonine-protein 
phosphatase PP1-gamma catalytic 
subunit 
PPP1CC 0.83 3.05 
A0A024RA52 
Proteasome subunit alpha 
type;Proteasome subunit alpha type-2 
PSMA2 0.81 2.55 
X5D2T3 60S ribosomal protein L10 RPL10 0.80 4.07 
P61026 Ras-related protein Rab-10 RAB10 0.79 2.57 
B7ZAY2 
Ras-related protein Rap-1b;Ras-
related protein Rap-1b-like 
protein;Ras-related protein Rap-1A 
RAP1B 0.77 4.39 
Q5U0D2 Transgelin TAGLN 0.77 2.63 
Q6IPH7  RPL14 0.76 4.33 
O15231 Zinc finger protein 185 ZNF185 0.76 4.13 
P51571 
Translocon-associated protein subunit 
delta 
SSR4 0.75 5.64 
J3KQ32 Obg-like ATPase 1 OLA1 0.74 4.78 
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A0A024RB14 
40S ribosomal protein S26;Putative 
40S ribosomal protein S26-like 1 
RPS26 0.74 3.59 
Q13509 Tubulin beta-3 chain TUBB3 0.74 4.60 
A0A024R7B7 
Hsp90 co-chaperone Cdc37;Hsp90 
co-chaperone Cdc37, N-terminally 
processed 
CDC37 0.72 5.11 
B7Z3K3 Inositol-3-phosphate synthase 1 ISYNA1 0.71 3.68 
B3KT06 Tubulin alpha-1B chain TUBA1B 0.71 6.93 
A0A024R1M8 Apolipoprotein L2 APOL2 0.71 1.95 
O43854 
EGF-like repeat and discoidin I-like 
domain-containing protein 3 
EDIL3 0.69 1.98 
P37802 Transgelin-2 TAGLN2 0.63 4.79 
P63172 Dynein light chain Tctex-type 1 DYNLT1 0.63 2.39 
B4DFL1 
Dihydrolipoyl 
dehydrogenase;Dihydrolipoyl 
dehydrogenase, mitochondrial 
DLD 0.61 2.36 
V9HW44 
Platelet-activating factor 
acetylhydrolase IB subunit beta 
HEL-S-
303 
0.60 3.84 
 
Table 1b: 
Protein ID Protein names 
Gene 
names 
Log2 
(HCAEC-
AMI vs 
HCAEC) 
-
LO
G(P
-
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valu
e) 
H3BPC4 SUMO-conjugating enzyme UBC9 UBE2I -1.68 1.38 
E7ENN3 Nesprin-1 SYNE1 -1.45 6.12 
F5H7F6 Microsomal glutathione S-transferase 1 MGST1 -1.45 5.54 
A0A1W2PR
F6 
Lysosome membrane protein 2 SCARB2 -1.43 4.16 
B3KPC7 
Actin-related protein 2/3 complex subunit 
5;Actin-related protein 2/3 complex 
subunit 5-like protein 
ARPC5L -1.43 3.29 
A8K651 
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
C1QBP -1.39 5.53 
Q9BQQ5 60S ribosomal protein L27a L27a -1.39 8.30 
P62851 40S ribosomal protein S25 RPS25 -1.38 6.19 
Q13201 
Multimerin-1;Platelet glycoprotein 
Ia*;155 kDa platelet multimerin 
MMRN1 -1.33 3.14 
Q9Y5B9 FACT complex subunit SPT16 SUPT16H -1.31 4.57 
Q96FQ6 Protein S100-A16 S100A16 -1.29 6.83 
Q6IBA2 
Activated RNA polymerase II 
transcriptional coactivator p15 
PC4 -1.25 7.05 
Q13151 
Heterogeneous nuclear ribonucleoprotein 
A0 
HNRNPA
0 
-1.21 4.49 
B4DWN1 
Vesicular integral-membrane protein 
VIP36 
LMAN2 -1.20 2.20 
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C9J3L8 
Translocon-associated protein subunit 
alpha 
SSR1 -1.20 5.57 
Q2TAM5 Transcription factor p65 RELA -1.17 6.14 
P29966 
Myristoylated alanine-rich C-kinase 
substrate 
MARCKS -1.15 6.06 
H0YN26 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
ANP32A -1.12 6.03 
Q53FJ5 
Prosaposin;Saposin-A;Saposin-B-
Val;Saposin-B;Saposin-C;Saposin-D 
PSAP -1.09 8.79 
Q13404 
Ubiquitin-conjugating enzyme E2 variant 
1 
UBE2V1 -1.09 3.47 
A0A140VJK
1 
Glutaredoxin-3 GLRX3 -1.06 4.43 
F8W6I7 
Heterogeneous nuclear ribonucleoprotein 
A1;Heterogeneous nuclear 
ribonucleoprotein A1, N-terminally 
processed;Heterogeneous nuclear 
ribonucleoprotein A1-like 2 
HNRNPA
1 
-1.05 5.46 
A0A024R3J7 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
STT3A 
hCG_2032
701 
-1.03 5.00 
Q9Y3U8 60S ribosomal protein L36 RPL36 -1.01 5.47 
P51858 Hepatoma-derived growth factor HDGF -1.00 4.74 
23 
 
F5GXX5 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
DAD1 
DAD1 -0.99 2.82 
Q5T7C4 
High mobility group protein B1;Putative 
high mobility group protein B1-like 1 
HMGB1 -0.99 7.17 
B4DTT0 N-acetylglucosamine-6-sulfatase 
DKFZp68
6E12166 
-0.97 8.94 
O14907 Tax1-binding protein 3 TAX1BP3 -0.97 3.69 
A0A024R4X
0 
NADH-cytochrome b5 reductase;NADH-
cytochrome b5 reductase 3;NADH-
cytochrome b5 reductase 3 membrane-
bound form;NADH-cytochrome b5 
reductase 3 soluble form 
CYB5R3 -0.97 7.22 
H9ZYJ2 Thioredoxin TXN -0.96 5.01 
B5BU25 Splicing factor U2AF 65 kDa subunit U2AF2 -0.96 8.00 
Q86U79 Adenosine kinase ADK -0.95 2.58 
L7RT18 Adapter molecule crk CRK -0.94 4.18 
V9HW48 
SH3 domain-binding glutamic acid-rich-
like protein 
HEL-S-
115 
-0.93 2.73 
A0A140VJF
4 
Biliverdin reductase A BLVRA -0.93 5.15 
E9PI87 Oxidoreductase HTATIP2 HTATIP2 -0.92 2.13 
J3KNF4 
Copper chaperone for superoxide 
dismutase 
CCS -0.92 4.48 
Q6FGV9 Phosphomevalonate kinase PMVK -0.92 2.92 
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P20700 Lamin-B1 LMNB1 -0.91 9.48 
Q6FGY1 Hippocalcin-like protein 1 HPCAL1 -0.91 3.83 
A0A024R25
8 
Ubiquilin-1;Ubiquilin-4 UBQLN1 -0.90 5.55 
Q53XX5 Cold-inducible RNA-binding protein CIRBP -0.90 3.80 
Q59H57 RNA-binding protein FUS FUS -0.90 3.77 
B4E324 
Carboxypeptidase;Lysosomal protective 
protein;Lysosomal protective protein 32 
kDa chain;Lysosomal protective protein 
20 kDa chain 
CTSA -0.89 4.30 
K7ESE8 Bleomycin hydrolase BLMH -0.89 3.32 
P46926 
Glucosamine-6-phosphate isomerase 
1;Glucosamine-6-phosphate isomerase 
GNPDA1 -0.88 4.45 
B7Z4K8 
Basic leucine zipper and W2 domain-
containing protein 2 
BZW2 -0.87 4.26 
B7Z2Z1 Scaffold attachment factor B1 SAFB -0.87 5.93 
Q6IRT1 
S-(hydroxymethyl)glutathione 
dehydrogenase;Alcohol dehydrogenase 
class-3 
ADH5 -0.87 4.62 
P15531 Nucleoside diphosphate kinase A NME1 -0.86 1.85 
A2A2D0 Stathmin STMN1 -0.86 8.87 
C9JFR7 Cytochrome c CYCS -0.84 6.18 
A8K2W3 Serum deprivation-response protein SDPR -0.83 
11.4
3 
F5GYN4 Ubiquitin thioesterase OTUB1 OTUB1 -0.81 5.20 
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O75436 
Vacuolar protein sorting-associated 
protein 26A 
VPS26A -0.81 2.38 
V9HW74 
Ubiquitin carboxyl-terminal 
hydrolase;Ubiquitin carboxyl-terminal 
hydrolase isozyme L1 
HEL-117 -0.79 1.94 
A0A0S2Z41
0 
3-hydroxyacyl-CoA dehydrogenase type-
2 
HSD17B1
0 
-0.79 4.64 
H3BPQ3 Protein NDRG4 NDRG4 -0.78 3.46 
Q5T9B9 Endoglin ENG -0.77 3.90 
A0A087X29
6 
Prostaglandin G/H synthase 1 PTGS1 -0.77 4.28 
J3K000 Xaa-Pro dipeptidase PEPD -0.76 3.38 
A0A024RA
V2 
ATP-dependent DNA helicase Q1 RECQL -0.76 5.90 
A0A024R3Z
6 
Basic leucine zipper and W2 domain-
containing protein 1 
BZW1 -0.75 5.44 
P18077 60S ribosomal protein L35a RPL35A -0.75 2.68 
Q6FH49 Nicotinamide N-methyltransferase NNMT -0.74 4.02 
V9HWI0 Alcohol dehydrogenase [NADP(+)] 
HEL-S-
165mP 
-0.74 7.43 
B3KMZ6 SUMO-activating enzyme subunit 2 UBA2 -0.74 3.60 
E9PJ81 UBX domain-containing protein 1 UBXN1 -0.74 2.45 
B4DIZ2 Ubiquitin-conjugating enzyme E2 K UBE2K -0.74 3.24 
A5PLK7 Protein RCC2 RCC2 -0.73 4.02 
B0YJ88 Radixin RDX -0.73 3.67 
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A0A024R88
3 
V-type proton ATPase subunit G 1 
ATP6V1G
1 
-0.73 3.30 
A0A024R3
W7 
Elongation factor 1-beta EEF1B2 -0.73 3.44 
Q5IST1 Serine/arginine-rich splicing factor 5 SFRS5 -0.71 2.49 
A0A024R8
W0 
Eukaryotic initiation factor 4A-
III;Eukaryotic initiation factor 4A-III, N-
terminally processed 
DDX48 -0.71 4.98 
Q6FHX6 Flap endonuclease 1 FEN1 -0.70 2.56 
Q53HS0 Glutamine--tRNA ligase QARS -0.70 5.15 
O95831 
Apoptosis-inducing factor 1, 
mitochondrial 
AIFM1 -0.70 2.02 
O15400 Syntaxin-7 STX7 -0.70 4.56 
Q5T123 
SH3 domain-binding glutamic acid-rich-
like protein 3 
SH3BGR
L3 
-0.69 4.48 
Q9HDC9 
Adipocyte plasma membrane-associated 
protein 
APMAP -0.69 2.58 
Q05BM8 
Polypeptide N-
acetylgalactosaminyltransferase;Polypept
ide N-acetylgalactosaminyltransferase 
1;Polypeptide N-
acetylgalactosaminyltransferase 1 soluble 
form 
GALNT1 -0.69 3.82 
Q9BRL5  CALM3 -0.69 2.73 
J3QRT5 Intercellular adhesion molecule 2 ICAM2 -0.69 2.31 
27 
 
F8WCF6 
Actin-related protein 2/3 complex subunit 
4 
ARPC4-
TTLL3 
-0.68 6.06 
I3L2L5 Protein FAM195B FAM195B -0.68 3.19 
B3KN57 Sorting nexin-2 SNX2 -0.68 5.10 
F8VQE1 LIM domain and actin-binding protein 1 LIMA1 -0.68 2.45 
D3DP46 Signal peptidase complex subunit 3 SPCS3 -0.68 2.27 
A0A024R9D
2 
Protein LYRIC MTDH -0.67 3.46 
P35580 Myosin-10 MYH10 -0.67 7.58 
K7ES31 
Eukaryotic translation initiation factor 3 
subunit K 
EIF3K -0.67 3.30 
J3KT73 60S ribosomal protein L38 RPL38 -0.66 6.00 
P62263 40S ribosomal protein S14 RPS14 -0.66 7.96 
P62495 
Eukaryotic peptide chain release factor 
subunit 1 
ETF1 -0.66 5.27 
Q53XC0 
Eukaryotic translation initiation factor 2 
subunit 1 
EIF2S1 -0.66 5.24 
Q96C90 
Protein phosphatase 1 regulatory subunit 
14B 
PPP1R14
B 
-0.65 2.71 
F5H2R5 Rho GDP-dissociation inhibitor 2 
ARHGDI
B 
-0.65 2.80 
A4D275 
Actin-related protein 2/3 complex subunit 
1B 
ARPC1B -0.64 2.92 
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Q14240 
Eukaryotic initiation factor 4A-
II;Eukaryotic initiation factor 4A-II, N-
terminally processed 
EIF4A2 -0.64 3.21 
B4E3A8 Leukocyte elastase inhibitor HEL57 -0.64 2.22 
A0A024R1K
8 
Splicing factor 3A subunit 1 SF3A1 -0.64 2.65 
H7BY10 60S ribosomal protein L23a RPL23A -0.64 3.71 
Q96IZ0 PRKC apoptosis WT1 regulator protein PAWR -0.64 4.69 
A8K719 Core-binding factor subunit beta CBFB -0.64 2.71 
A0A024RDB
0 
Ubiquitin-like modifier-activating 
enzyme 6 
UBE1L2 -0.64 7.12 
A0A0A6YYJ
8 
Putative RNA-binding protein Luc7-like 
2 
LUC7L2 -0.64 3.62 
A0A140VJP
5 
S-adenosylmethionine synthase isoform 
type-2;S-adenosylmethionine synthase 
MAT2A -0.64 4.18 
Q53R19 
Actin-related protein 2/3 complex subunit 
2 
ARPC2 -0.62 3.86 
A0A1X7SBZ
2 
Probable ATP-dependent RNA helicase 
DDX17 
DDX17 -0.62 9.54 
A9UK01 Rho GTPase-activating protein 18 
ARHGAP
18 
-0.61 5.11 
A0A024RB8
5 
Proliferation-associated protein 2G4 PA2G4 -0.61 6.66 
V9HW41 Ubiquitin-conjugating enzyme E2 N HEL-S-71 -0.61 3.01 
Q5VVD0 60S ribosomal protein L11 RPL11 -0.61 4.27 
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P51991 
Heterogeneous nuclear ribonucleoprotein 
A3 
HNRNPA
3 
-0.61 9.09 
A0A024R5Q
7 
Adenylosuccinate synthetase isozyme 2 ADSS -0.61 6.02 
Q59GU6 Sorting nexin-1 SNX1 -0.61 3.93 
P13010 
X-ray repair cross-complementing 
protein 5 
XRCC5 -0.60 6.59 
C9J9K3 40S ribosomal protein SA RPSA -0.60 7.71 
A0A0A0MR
M8 
Unconventional myosin-VI MYO6 -0.60 3.14 
L7RXH5 
Mitogen-activated protein 
kinase;Mitogen-activated protein kinase 
3 
MAPK3 -0.60 6.02 
V9HWC2 Protein deglycase DJ-1 
HEL-S-
67p 
-0.60 6.11 
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